GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Luoxin Pharmaceutical Group Stock Co Ltd (OTCPK:SLUXY) » Definitions » EV-to-EBIT

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) EV-to-EBIT : 10.34 (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shandong Luoxin Pharmaceutical Group Stock Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shandong Luoxin Pharmaceutical Group Stock Co's Enterprise Value is $670.6 Mil. Shandong Luoxin Pharmaceutical Group Stock Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 was $64.9 Mil. Therefore, Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT for today is 10.34.

The historical rank and industry rank for Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT or its related term are showing as below:

SLUXY's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.125
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Shandong Luoxin Pharmaceutical Group Stock Co's Enterprise Value for the quarter that ended in Mar. 2017 was $829.7 Mil. Shandong Luoxin Pharmaceutical Group Stock Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 was $64.9 Mil. Shandong Luoxin Pharmaceutical Group Stock Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was 7.82%.


Shandong Luoxin Pharmaceutical Group Stock Co EV-to-EBIT Historical Data

The historical data trend for Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Luoxin Pharmaceutical Group Stock Co EV-to-EBIT Chart

Shandong Luoxin Pharmaceutical Group Stock Co Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.03 3.64 11.19 7.98 8.74

Shandong Luoxin Pharmaceutical Group Stock Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.55 7.92 11.18 8.74 20.27

Competitive Comparison of Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT falls into.



Shandong Luoxin Pharmaceutical Group Stock Co EV-to-EBIT Calculation

Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=670.560/64.851
=10.34

Shandong Luoxin Pharmaceutical Group Stock Co's current Enterprise Value is $670.6 Mil.
Shandong Luoxin Pharmaceutical Group Stock Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $64.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Luoxin Pharmaceutical Group Stock Co  (OTCPK:SLUXY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Shandong Luoxin Pharmaceutical Group Stock Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2017 ) =EBIT / Enterprise Value (Q: Mar. 2017 )
=64.851/829.6656
=7.82 %

Shandong Luoxin Pharmaceutical Group Stock Co's Enterprise Value for the quarter that ended in Mar. 2017 was $829.7 Mil.
Shandong Luoxin Pharmaceutical Group Stock Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $64.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Luoxin Pharmaceutical Group Stock Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Shandong Luoxin Pharmaceutical Group Stock Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Business Description

Traded in Other Exchanges
N/A
Address
Shandong Luoxin Pharmaceutical Group Stock Co Ltd along with its subsidiaries is engaged in the manufacturing and selling of pharmaceutical products. It is involved in the research and development of LXI-15028, a potassium-competitive acid blocker, which is in phase III development for the treatment of reflux esophagitis and other acid-related gastrointestinal diseases; and LXI-15029, an ATP mTOR kinase inhibitor that acts as potent and selective dual inhibitors of mTORC1 and mTORC2 that controls the process of tumor formation and growth. The company mainly operates in the People's Republic of China.

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Headlines

No Headlines